Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Pipeline Review, H2 2016

Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Pipeline Review, H2 2016
Published Jul 20, 2016
102 pages — Published Jul 20, 2016
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Pipeline Review, H2 2016, provides in depth analysis on Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) targeted pipeline therapeutics.

The report provides comprehensive information on the Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22)
- The report reviews Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) targeted therapeutics and enlists all their major and minor projects
- The report assesses Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies&

  
Source:
Document ID
GMDHC0394TDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents26
  List of Tables61
  List of Figures71
Introduction81
  Global Markets Direct Report Coverage81
Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) Overview91
Therapeutics Development104
  Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) Products under Development by Stage of Development101
  Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) Products under Development by Therapy Area111
  Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) Products under Development by Indication122
Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) Pipeline Products Glance142
  Late Stage Products141
  Early Stage Products151
Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) Products under Development by Companies165
Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) Therapeutics Assessment216
  Assessment by Monotherapy/Combination Products211
  Assessment by Mechanism of Action221
  Assessment by Route of Administration232
  Assessment by Molecule Type252
Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) Companies Involved in Therapeutics Development2714
  Beta Pharma, Inc.271
  Eli Lilly and Company281
  G1 Therapeutics, Inc.291
  Jiangsu Hengrui Medicine Co., Ltd.301
  Novartis AG311
  Onconova Therapeutics, Inc.321
  Pfizer Inc.331
  Presage Biosciences, Inc.341
  Sihuan Pharmaceutical Holdings Group Ltd.351
  Teijin Pharma Limited361
  Theryte Limited371
  Tiziana Life Sciences Plc381
  Vichem Chemie Research Ltd.391
  ViroStatics srl401
Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) Drug Profiles4143
  abemaciclib Drug Profile415
  BPI-1178 Drug Profile461
  C-1748 Drug Profile472
  FLX-925 Drug Profile491
  G-1T28 Drug Profile502
  G-1T38 Drug Profile521
  GZ-381 Drug Profile531
  milciclib Drug Profile542
  MMD-37K Drug Profile561
  ON-123300 Drug Profile571
  palbociclib Drug Profile5810
  ribociclib succinate Drug Profile684
  SHR-6390 Drug Profile721
  Small Molecule to Inhibit CDK 4 and 6 for Rheumatoid Arthritis Drug Profile731
  Small Molecule to Inhibit CDK4 and CDK6 for Acute Kidney Injury and Breast Cancer Drug Profile741
  Small Molecule to Inhibit CDK4 and CDK6 for Breast Cancer Drug Profile751
  Small Molecule to Inhibit CDK4, CDK6 and CDK9 for HPV Associated Cancers Drug Profile761
  Small Molecule to Inhibit CDK4, CDK6 and CDK9 for HSV Infections Drug Profile771
  Small Molecule to Inhibit CDK4, CDK6 and CDK9 for Oncology Drug Profile781
  Small Molecules to Inhibit CDK4 for Oncology Drug Profile791
  Small Molecules to Inhibit CDK4, CDK6 and CDK9 for EBV Infections Drug Profile801
  THR-53 Drug Profile811
  voruciclib Drug Profile822
Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) Dormant Projects842
Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) Discontinued Products861
Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) Featured News &Press Releases8714
  Jul 06, 2016: Study Tests New Breast Cancer Drug In African American Women871
  Jun 03, 2016: Presage Biosciences Appoints David Johnson to Board of Directors881
  Jun 03, 2016: Lilly Announces Results From MONARCH 1 Trial Of Abemaciclib Monotherapy881
  May 31, 2016: Lilly Announces Webcast To Discuss Abemaciclib Data891
  May 23, 2016: Investigational CDK4/6 inhibitor abemaciclib is active against a range of cancer types892
  May 18, 2016: Eli Lilly to Present final phase 2 monotherapy data on CDK 4 and 6 inhibitor abemaciclib in metastatic breast cancer at ASCO911
  May 18, 2016: MONALEESA-2 trial of Novartis' LEE011 (ribociclib) stopped due to positive efficacy results at interim analysis in HR+/HER2- advanced breast cancer921
  May 10, 2016: Health Canada approves new first-line treatment for women living with metastatic breast cancer922
  Apr 20, 2016: Onconova Announces Novel Dual Targeting of ARK5 and CDK4/6 by Pre-clinical Compound, ON 123300, in Presentation at 2016 American Association of Cancer Research (AACR) Annual Meeting941
  Apr 19, 2016: Presage Biosciences Presents Data Demonstrating Tumor Growth Inhibition by Voruciclib and Proteasome Inhibitors Superior to Single Agents in Model of Triple Negative Breast Cancer941
  Apr 19, 2016: Pfizer Announces Positive Top-Line Results For Phase 3 PALOMA-2 Clinical Trial Of IBRANCE (Palbociclib)952
  Apr 15, 2016: G1 Therapeutics to Present Preliminary clinical data on CDK4/6 Inhibitor G1T28 at the 2016 American Association for Cancer Research Annual Meeting971
  Apr 15, 2016: G1 Therapeutics to Present Preclinical Data on CDK4/6 Inhibitor G1T38 at the 2016 American Association for Cancer Research Annual Meeting981
  Mar 14, 2016: New agent overcomes drug resistance in HER2-positive breast cancer preclinical study shows982
  Mar 07, 2016: New therapeutic target in myeloma discovered1001
Appendix1012
  Methodology1011
  Coverage1011
  Secondary Research1011
  Primary Research1011
  Expert Panel Validation1011
  Contact Us1011
  Disclaimer1021

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Pipeline Review, H2 2016" Jul 20, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Cyclin-Dependent-Kinase-4-Cell-Division-Protein-Kinase-4-or-PSK-J3-or-CDK4-or-EC-2-7-11-22-Pipeline-Review-H2-2016-2088-16276>
  
APA:
Global Markets Direct - Market Research. (2016). Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Pipeline Review, H2 2016 Jul 20, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Cyclin-Dependent-Kinase-4-Cell-Division-Protein-Kinase-4-or-PSK-J3-or-CDK4-or-EC-2-7-11-22-Pipeline-Review-H2-2016-2088-16276>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.